2022 Revenues ($USD) : $3,578,100,000
2022 R&D spend : $253,600,000
2022 Number of Employees : 8,000
Fiscal Year End : 6/30/2022
Company CEO : Michael Farrell, CEO

Founded by Peter Farrell in Australia in 1989, ResMed remains a family affair today, with his son Michael "Mick" Farrell now CEO. It’s a position Mick Farrell has held since his father transitioned into a non-executive role in 2013. Now headquartered in San Diego, ResMed develops cloud-connected medical devices for respiratory diseases. Among its offerings are continuous positive airway pressure (CPAP) machines for sleep apnea and ventilators for treating chronic obstructive pulmonary disease (COPD) and other respiratory conditions. Health providers have used the company’s devices as alternatives to invasive ventilators during the COVID-19 pandemic. With competitor Philips sidelined by a massive recall until at least 2023, ResMed has grown as fast as its supply chain allows. In 2022, Lucile Blaise became president of ResMed’s Sleep & Respiratory Care business, replacing Jim Hollingshead after he left to become CEO of Insulet. The company also bought digital insomnia therapy app Somnio developer Mementor and announced a $1 billion deal to buy German software company Medifox Dan by the end of the year. –SW and JH